Gastric Cancer Market
Gastric Cancer Market Size, Share & Trends Analysis Report by Testing Type (Chest X-Ray, Computed Tomography (CT OR CAT) Scan, Laparoscopy, MRI Scan, PET Scan and Others), by Treatment Type (Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy and Immunotherapy), and by End-User (Hospitals & Clinics, Specialized Cancer Treatment Centers and Others), Forecast Period (2026-2035)
Industry Overview
Gastric cancer market was valued at $7.5 billion in 2025 and is projected to reach $16.5 billion by 2035, growing at a CAGR of 8.3% during the forecast period (2026-2035). The global market for gastric cancer diagnostics and treatment is experiencing steady expansion, supported by the rising incidence of the disease and increased awareness regarding early detection. Advancements in imaging technologies and diagnostic procedures have significantly improved the accuracy and timeliness of diagnosis, encouraging broader adoption across healthcare systems. In parallel, continuous innovation in treatment approaches, including precision-based therapies and combination regimens, is enhancing patient outcomes and driving demand. The growing availability of specialized treatment facilities and improved healthcare infrastructure in emerging regions further contribute to market development. Additionally, increased investments in research and clinical development are fostering the introduction of more effective therapeutic options. Collectively, these factors are expected to sustain consistent market growth over the forecast period.
Market Dynamics
Rising Adoption of Advanced Diagnostic Imaging Technologies
The increasing integration of advanced imaging modalities is significantly shaping the gastric cancer market. Technologies such as computed tomography, magnetic resonance imaging, and positron emission tomography are being widely utilized to enhance diagnostic accuracy and staging precision. These tools enable early detection, which is critical for improving survival outcomes and treatment planning. Healthcare providers are prioritizing investments in high-resolution imaging systems to support timely diagnosis. Additionally, ongoing technological advancements are making these diagnostic solutions more accessible across both developed and emerging regions. The growing emphasis on preventive healthcare further supports the demand for comprehensive diagnostic procedures. As a result, diagnostic innovation remains a key trend driving market expansion.
Expansion of Specialized Cancer Treatment Facilities
The growth of specialized cancer treatment centers is playing a crucial role in strengthening the gastric cancer market. These facilities are equipped with advanced infrastructure and multidisciplinary expertise to provide comprehensive care. Patients increasingly prefer specialized centers due to the availability of integrated diagnostic and therapeutic services. Governments and private investors are supporting the development of oncology-focused institutions to address the rising cancer burden. Improved access to skilled healthcare professionals and advanced treatment technologies is enhancing the quality of care delivered. Additionally, collaborations between hospitals and research organizations are fostering innovation and knowledge sharing. This expansion of specialized care networks is contributing to improved treatment accessibility and overall market growth.
Market Segmentation
- Based on the testing type, the market is segmented into Chest X-Ray, Computed Tomography (CT OR CAT) scan, laparoscopy, MRI scan, PET scan and others.
- Based on the treatment type, the market is segmented into chemotherapy, radiation therapy, surgery, targeted therapy and immunotherapy.
- Based on the end-user, the market is segmented into hospitals & clinics, specialized cancer treatment centers and others.
Widespread Utilization of Computed Tomography in Diagnostic Pathways
Computed tomography has established itself as the most widely adopted diagnostic modality due to its precision in tumor detection and staging. Its ability to provide detailed cross-sectional imaging supports accurate clinical decision-making and treatment planning. The segment continues to expand with the integration of advanced imaging software and improved scan resolution. Increasing demand for early and reliable diagnosis is encouraging healthcare providers to prioritize such technologies. Major industry participants, including Siemens Healthineers, GE HealthCare, and Koninklijke Philips N.V., are enhancing product portfolios with innovative imaging solutions. Recent developments focus on faster scanning techniques and reduced radiation exposure. These advancements are reinforcing its dominant role in diagnostic practices.
Rapid Advancement of Immunotherapy in Treatment Landscape
Immunotherapy is witnessing the fastest growth within treatment approaches, driven by its capacity to improve long-term survival outcomes. The segment is benefiting from ongoing breakthroughs in immune checkpoint inhibitors and personalized medicine strategies. Pharmaceutical companies such as Merck & Co., Bristol-Myers Squibb, and AstraZeneca are actively expanding their oncology pipelines. Increasing approval of novel biologics and combination therapies is accelerating clinical adoption. The shift toward biomarker-based treatment selection is further strengthening its effectiveness and demand. Additionally, global clinical trials and research investments are supporting continuous innovation. This progress is positioning immunotherapy as a transformative force in modern cancer treatment.
Regional Outlook
The global gastric cancer market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Established Leadership Backed by Advanced Healthcare Systems
North America continues to maintain a strong position, supported by well-developed healthcare infrastructure and high adoption of advanced diagnostic and treatment technologies. The region benefits from significant research funding and a strong presence of leading pharmaceutical and biotechnology firms. Companies such as Pfizer Inc., Merck & Co., and Bristol-Myers Squibb are actively engaged in expanding therapeutic innovations. Increasing awareness regarding early detection and routine screening practices is further contributing to market stability. Recent trends indicate a growing preference for precision medicine and immunotherapy-based approaches. Strategic partnerships and ongoing clinical trials are enhancing treatment accessibility and effectiveness. These combined factors are sustaining the region’s steady progression in the market.
Rapid Expansion Driven by Improving Healthcare Access
Asia-Pacific is emerging as a high-growth region due to rising healthcare investments and increasing prevalence of gastric cancer. Expanding medical infrastructure and improved access to diagnostic services are encouraging early-stage detection across developing economies. Regional and global players, including Takeda Pharmaceutical Company and Daiichi Sankyo Company Ltd., are strengthening their presence through strategic initiatives. Growing awareness programs and government-led healthcare reforms are also supporting market development. Recent trends highlight increased adoption of advanced imaging technologies and modern treatment approaches. Additionally, the rise of medical tourism is contributing to higher patient volumes in specialized centers. This evolving landscape is positioning the region as a key contributor to future market growth.
Market Players Outlook
The major companies operating in the global Gastric Cancer market include AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. and Merck & Co., Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In March 2025, the U.S. Food and Drug Administration granted full approval to pembrolizumab in combination with trastuzumab and chemotherapy for first-line treatment of HER2-positive gastric or gastroesophageal junction adenocarcinoma, based on results from the KEYNOTE-811 trial. The regimen demonstrated improved overall survival of around 20 months compared to less than 15 months in earlier standards such as the ToGA study.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global gastric cancer market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Gastric Cancer Market Sales Analysis – Testing Type | Treatment Type | End-User | ($ Million)
- Gastric Cancer Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Gastric Cancer Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Gastric Cancer Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Gastric Cancer Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Gastric Cancer Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Gastric Cancer Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Gastric Cancer Market Revenue and Share by Manufacturers
- Gastric Cancer Manufacturers Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AstraZeneca plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Bristol-Myers Squibb Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Eli Lilly and Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Hoffmann-La Roche Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co., Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- AstraZeneca plc
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Global Gastric Cancer Market Sales Analysis by Testing Type ($ Million)
- Chest X-Ray
- Computed Tomography (CT OR CAT) Scan
- Laparoscopy
- MRI Scan
- PET Scan
- Others
- Global Gastric Cancer Market Sales Analysis by Treatment Type ($ Million)
- Chemotherapy
- Radiation Therapy
- Surgery
- Targeted Therapy
- Immunotherapy
- Global Gastric Cancer Market Sales Analysis by End-User ($ Million)
- Hospitals & Clinics
- Specialized Cancer Treatment Centers
- Others
- Regional Analysis
- North American Gastric Cancer Market Sales Analysis – Testing Type | Treatment Type | End-User | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Gastric Cancer Market Sales Analysis – Testing Type | Treatment Type | End-User | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Gastric Cancer Market Sales Analysis – Testing Type | Treatment Type | End-User | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Gastric Cancer Market Sales Analysis – Testing Type | Treatment Type | End-User| Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Astellas Pharma Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BeiGene Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Boehringer Ingelheim GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol-Myers Squibb Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Celltrion, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Chugai Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Daiichi Sankyo Company, Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Gastric Cancer Market Research and Analysis by Testing Type, 2025–2035 ($ Million)
2. Global Chest X-Ray For Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Computed Tomography Scan For Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Laparoscopy For Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global MRI Scan For Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global PET Scan For Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Others Gastric Cancer Test Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Gastric Cancer Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
9. Global Chemotherapy For Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Radiation Therapy For Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Surgery For Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Targeted Therapy For Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Immunotherapy For Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Gastric Cancer Market Research and Analysis by End-User, 2025–2035 ($ Million)
15. Global Gastric Cancer For Hospitals & Clinics Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Gastric Cancer For Specialized Cancer Treatment Centers Market Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Gastric Cancer For Others Market Research and Analysis by Region, 2025–2035 ($ Million)
18. Global Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
19. North American Gastric Cancer Market Research and Analysis by Country, 2025–2035 ($ Million)
20. North American Gastric Cancer Market Research and Analysis by Testing Type, 2025–2035 ($ Million)
21. North American Gastric Cancer Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
22. North American Gastric Cancer Market Research and Analysis by End-User, 2025–2035 ($ Million)
23. European Gastric Cancer Market Research and Analysis by Country, 2025–2035 ($ Million)
24. European Gastric Cancer Market Research and Analysis by Testing Type, 2025–2035 ($ Million)
25. European Gastric Cancer Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
26. European Gastric Cancer Market Research and Analysis by End-User, 2025–2035 ($ Million)
27. Asia-Pacific Gastric Cancer Market Research and Analysis by Country, 2025–2035 ($ Million)
28. Asia-Pacific Gastric Cancer Market Research and Analysis by Testing Type, 2025–2035 ($ Million)
29. Asia-Pacific Gastric Cancer Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
30. Asia-Pacific Gastric Cancer Market Research and Analysis by End-User, 2025–2035 ($ Million)
31. Rest of the World Gastric Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
32. Rest of the World Gastric Cancer Market Research and Analysis by Testing Type, 2025–2035 ($ Million)
33. Rest of the World Gastric Cancer Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
34. Rest of the World Gastric Cancer Market Research and Analysis by End-User, 2025–2035 ($ Million)
1. Global Gastric Cancer Market Share by Testing Type, 2025 Vs 2035 (%)
2. Global Chest X-Ray For Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
3. Global Computed Tomography (CT OR CAT) Scan For Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
4. Global Laparoscopy For Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
5. Global MRI Scan For Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
6. Global PET Scan For Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
7. Global Other Gastric Cancer Test Market Share by Region, 2025 Vs 2035 (%)
8. Global Gastric Cancer Market Share by Treatment Type, 2025 Vs 2035 (%)
9. Global Chemotherapy For Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
10. Global Radiation Therapy For Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
11. Global Surgery For Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
12. Global Targeted For Therapy Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
13. Global Immunotherapy For Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
14. Global Gastric Cancer Market Share by End-User, 2025 Vs 2035 (%)
15. Global Gastric Cancer For Hospitals & Clinics Market Share by Region, 2025 Vs 2035 (%)
16. Global Gastric Cancer For Specialized Cancer Treatment Centers Market Share by Region, 2025 Vs 2035 (%)
17. Global Gastric Cancer For Other Market Share by Region, 2025 Vs 2035 (%)
18. Global Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
19. Global Based Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
20. Global Gastric Cancer Market Share by Region, 2025 Vs 2035 (%)
21. US Gastric Cancer Market Size, 2025–2035 ($ Million)
22. Canada Gastric Cancer Market Size, 2025–2035 ($ Million)
23. UK Gastric Cancer Market Size, 2025–2035 ($ Million)
24. France Gastric Cancer Market Size, 2025–2035 ($ Million)
25. Germany Gastric Cancer Market Size, 2025–2035 ($ Million)
26. Italy Gastric Cancer Market Size, 2025–2035 ($ Million)
27. Spain Gastric Cancer Market Size, 2025–2035 ($ Million)
28. Russia Gastric Cancer Market Size, 2025–2035 ($ Million)
29. Rest of Europe Gastric Cancer Market Size, 2025–2035 ($ Million)
30. India Gastric Cancer Market Size, 2025–2035 ($ Million)
31. China Gastric Cancer Market Size, 2025–2035 ($ Million)
32. Japan Gastric Cancer Market Size, 2025–2035 ($ Million)
33. South Korea Gastric Cancer Market Size, 2025–2035 ($ Million)
34. Australia and New Zealand Gastric Cancer Market Size, 2025–2035 ($ Million)
35. ASEAN Economies Gastric Cancer Market Size, 2025–2035 ($ Million)
36. Rest of Asia-Pacific Gastric Cancer Market Size, 2025–2035 ($ Million)
37. Latin America Gastric Cancer Market Size, 2025–2035 ($ Million)
38. Middle East and Africa Gastric Cancer Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
